You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. CYCLO THERAPEUTICS INC - ORDINARY SHARES - CLASS A

Cyclo Therapeutics Inc - Ordinary Shares - Class A XNAS: CYTH

Cyclo Therapeutics Inc - Ordinary Shares - Class A Live Share Price Today, Share Analysis and Chart

Download real time

0.66 -0.04 (-5.71%)

63.13% Fall from 52W High

76,360 XNAS Volume

XNAS 17 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share

Cyclo Therapeutics Inc - O... Key Metrics

Select

Market Capitalization

Low in industry
21.6

PE TTM

Negative PE TTM
-0.9

Price to Book

Negative Price to Book
-1.6

Institutional holding current Qtr %

Low in industry
6.9

Revenue Growth Qtr YoY %

Negative Revenue Growth Qtr YoY %
-52.8

Operating Revenue growth TTM %

Negative Operating Revenue growth TTM %
-8.5

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-85.1

Net Profit TTM Growth %

Negative Net Profit TTM Growth %
-27.9

Operating Profit Margin Qtr %

Negative Operating Profit Margin Qtr %
-3,546

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-2,834.1

Piotroski Score

Below industry Median
1

Rel Perf vs Sector quarter%

9.4

ROE Annual %

Negative ROE Annual %
-730.5

RoA Annual %

Negative RoA Annual %
-229.7
All financials are in USD Million and price data in USD
VIEW MORE

10

S

17

W

0

O

2

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Cyclo Therapeutics Inc - O... Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '25Dec '2602040Actual RevenueAvg. Estimate
Inline

Cyclo Therapeutics Inc - Ordinary Shares - Class A's Revenue was higher than average estimate 1 time in past 2 years

EPS forecast

Current EPS
-1.2
Avg. Estimate
-0.7
Low Estimate
-0.8
High Estimate
-0.6
Current EPS
Avg. Estimate
Hit

EPS is expected to grow by 45.5% in FY24

Consensus Recommendation

3 ANALYST Recommendations
BUY

Created with Highcharts 7.2.22Hold1Strong Buy

The consensus recommendation from 3 analysts for Cyclo Therapeutics Inc - Ordinary Shares - Class A is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Cyclo Therapeutics Inc - O... Stock Analysis

Cyclo Therapeutics Inc - O... stock analysis with key metrics, changes, and trends.

Cyclo Therapeutics Inc - O... MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$1.08 M13.09%positive

Annual Revenue rose 13.09%, in the last year to $1.08 M. Its sector's average revenue growth for the last fiscal year was 7.47%.

Annual Net Profit$20.06 M3.41%negative

Annual Net Profit fell 3.41% in the last year to $20.06 M. Its sector's average net profit growth for the last fiscal year was -32.47%.

Price to Earning Ratio-0.87-negative

Price to Earning Ratio is -0.87, which is negative.

Stock Price$0.66-60%negative

Stock Price fell 60% and underperformed its sector by 69.36% in the past year.

Quarterly Revenue$0.23 M52.82%negative

Quarterly Revenue fell 52.82% YoY to $0.23 M. Its sector's average revenue growth YoY for the quarter was 5.97%.

Quarterly Net profit$8.83 M85.12%negative

Quarterly Net profit fell 85.12% YoY to $8.83 M. Its sector's average net profit growth YoY for the quarter was -47.43%.

Debt to Equity Ratio0.22-positive

Debt to Equity Ratio of 0.22 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-730.48 %-730.48%negative

Return on Equity(ROE) for the last financial year was -730.48%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding4.55 %0%negative

Mutual Fund Holding decreased by 0% in the last quarter to 4.55.

Institutional Holding6.93 %-0.04%negative

Institutional Holding decreased by 0.04% in the last quarter to 6.93.

VIEW LESS


Loading data..

Cyclo Therapeutics Inc - Ordinary Shares - Class A - Company Profile

What does Cyclo Therapeutics Inc - Ordinary Shares - Class A do?

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.

Cyclo Therapeutics Inc - Ordinary Shares - Class A Management structure

All Gross Remunerations are in USD
Mr. N. Scott Fine
Director and Chief Executive Officer
672.89 K
2023
Gross Remuneration
Year
Mr. Michael Lisjak
Chief Regulatory Officer and Senior Vice President, Business Development
473.21 K
2023
Gross Remuneration
Year
Mr. Joshua M. Fine
Chief Financial Officer, Principal Accounting Officer and Secretary
463.98 K
2023
Gross Remuneration
Year
Dr. Jeffrey L. Tate, PhD
Director and Chief Operating Officer
-
2023
Gross Remuneration
Year

Cyclo Therapeutics Inc - Ordinary Shares - Class A Board of directors

All Gross Remunerations are in USD
Mr. Markus W. Sieger
Chairman of the Board
66.38 K
2023
Gross Remuneration
Year
Mr. F. Patrick Ostronic
Vice Chairman of the Board
41.25 K
2023
Gross Remuneration
Year
Mr. William S. Shanahan
Independent Director
40.13 K
2023
Gross Remuneration
Year
Dr. Randall M. Toig
Independent Director
35.63 K
2023
Gross Remuneration
Year
Mr. C.E. Rick Strattan
Independent Director
33 K
2023
Gross Remuneration
Year
Mr. William Conkling
Independent Director
13.33 K
2023
Gross Remuneration
Year

Cyclo Therapeutics Inc - Ordinary Shares - Class A FAQ

How is Cyclo Therapeutics Inc - Ordinary Shares - Class A today?
Cyclo Therapeutics Inc - Ordinary Shares - Class A today is trading in the red, and is down by -5.71% at 0.66.
Cyclo Therapeutics Inc - Ordinary Shares - Class A is currently trading down -5.71% on an intraday basis. In the past week the stock fell -10.81%. stock has been up 15.79% in the past quarter and fell -60.00% in the past year. You can view this in the overview section.